Truist Securities Maintains Buy on Marinus Pharma, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee maintains a Buy rating on Marinus Pharma (NASDAQ:MRNS) with a $10 price target.
June 18, 2024 | 5:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Joon Lee maintains a Buy rating on Marinus Pharma with a $10 price target, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $10 price target by Truist Securities suggests strong confidence in Marinus Pharma's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100